RECOMBINANT NONXIMMUNOGENIC STAPHYLOKINASE IN THE TREATMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
https://doi.org/10.29001/2073-8552-2016-31-2-51-54
Abstract
The aim of the study was to determine the efficacy of a 15 mg single bolus of new domestic thrombolytic agent Fortelysin versus Tenecteplase in patients with acute myocardial infarction. A total of 78 patients within 6 hours of ST-elevation acute myocardial infarction (STEMI) were randomized into two groups. We analyzed clinical and medical history of the patients, timelines, and the effectiveness of the reperfusion approaches. It has been found that the application of a 15 mg single bolus Fortelysin was comparable in efficacy and safety with Tenecteplase in a standard dose based on body weight.
About the Authors
Ya. V. Alekseeva
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
E. V. Vyshlov
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
V. A. Markov
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
References
1. Маркин С.С., Семенов А.М., Марков В.А. и др. Исследование нового отечественного тромболитического препарата Фортелизин® у больных острым инфарктом миокарда // Сибирский медицинский журнал (Томск). – 2012. – № 1. – С. 27–32.
2. Сулимов В.А. Тромболизис или первичное чрескожное коронарное вмешательство при инфаркте миокарда с подъемом ST-сегмента? Исследование STREAM // Рациональная фармакотерапия в кардиологии. – 2013. – № 9(6). – С. 640– 649.
3. Gulin D.A., Mukhametova L.I., Markin S.S. et al. New thrombolytic agent Fortelysin: kinetics of plasminogen activation and fibrinolysis // VI Moscow International Congress “Biotechnology: State of the Art and Prospects of Development”. – 2011. – P. 28.
4. Kunadian V., Gibson C.M. Thrombolytics and myocardial infarction // Cadriovasc. Therapeutics. – 2012. – No. 30(2). – Р. e81–e88.
5. Liu F., Guo Q., Xie G. et al. Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta(Analysis // PLoS One. 2015. – No. 10(12). – P. e0146207.
6. Sinnaeve P.R., Armstrong P.W., Gershlick A.H. et al. ST-Segment elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention // Circulation. – 2014. – Vol. 130. – P. 1139–1145.
7. Tanswell P., ModiAffiliated withDepartment of Pharmacokinetics and Metabolism, Genentech IncALZA Corporation N., ModiAffiliated withDepartment of Pharmacokinetics and Metabolism, Genentech IncALZA Corporation N., Danays T. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction // Clinical Pharmacokinetics. – 2002. – Vol. 41. – P. 1229–1245.
8. Vanderschueren S., Stockx L., Wilms G. et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase // Circulation. – 1995. – Vol. 92(8). – P. 2050– 2057.
Review
For citations:
Alekseeva Ya.V., Vyshlov E.V., Markov V.A. RECOMBINANT NONXIMMUNOGENIC STAPHYLOKINASE IN THE TREATMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Siberian Journal of Clinical and Experimental Medicine. 2016;31(2):51-54. (In Russ.) https://doi.org/10.29001/2073-8552-2016-31-2-51-54
Views:
633
.png)
Email this article 